In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive anti...
Hlavní autoři: | Rosás-Umbert, M, Ruiz-Riol, M, Fernández, MA, Marszalek, M, Coll, P, Manzardo, C, Cedeño, S, Miró, JM, Clotet, B, Hanke, T, Moltó, J, Mothe, B, Brander, C, BCN02 study group |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Frontiers Media
2020
|
Podobné jednotky
-
In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
Autor: Miriam Rosás-Umbert, a další
Vydáno: (2020-03-01) -
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Autor: Beatriz Mothe, a další
Vydáno: (2020-05-01) -
HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: Safety, immunogenicity and effect on the viral reservoir (Study BCN02)
Autor: Mothe, B, a další
Vydáno: (2020) -
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome
Autor: Bruna Oriol-Tordera, a další
Vydáno: (2022-04-01) -
Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)
Autor: Mothe, B, a další
Vydáno: (2019)